Table 1.
Pretreatment of GSU risk factors
| Factor | Value | No GSU, N (%) | GSU, N (%) |
|---|---|---|---|
| Age | 0(<60) | 26 (7.30) | 17(4.78) |
| 1(60–70) | 142(39.88) | 60(16.85) | |
| 2(>70) | 78(21.91) | 33(9.27) | |
| BMI | 0(<18 kg/m²) | 4(1.12) | 3(0.84) |
| 1(18–24 kg/m²) | 85(23.88) | 42(11.79) | |
| 2(>24 kg/m²) | 157(44.10) | 65(18.26) | |
| PSA | 0(<10 µg/L) | 41(11.52) | 27(7.58) |
| 1(10–20 µg/L) | 70(19.66) | 28(7.87) | |
| 2(>20 µg/L) | 135(37.92) | 55(15.44) | |
| Positive cores | 0(<3) | 76(21.34) | 60(16.85) |
| 1(≥3) | 170(47.75) | 50(14.04) | |
| % of positive cores | 0(<50%) | 116(32.58) | 60(16.85) |
| 1(≥50%) | 130(36.52) | 50(14.04) | |
| Prostate volume | 0(<40 ml) | 98(27.53) | 69(19.38) |
| 1(40–60 ml) | 81(22.75) | 25(7.02) | |
| 2(>60 ml) | 67(18.82) | 16(4.49) | |
| PSAD | 0(<0.25) | 50(14.04) | 32(8.99) |
| 1(0.25–0.5) | 59(16.57) | 22(6.18) | |
| 2(0.5-1) | 55(15.45) | 23(6.46) | |
| 3(>1) | 82(23.03) | 33(9.27) | |
| PI-RADS | 3 | 41(11.52) | 6(16.85) |
| 4 | 140(39.33) | 63(17.70) | |
| 5 | 65(18.26) | 41(11.52) | |
| Clinical stage | <T3 | 162(45.50) | 61(17.13) |
| ≥T3 | 84(23.60) | 49(13.76) | |
| Lymphatic metastasis | yes | 23(65.71) | 2(0.56) |
| no | 223(62.64) | 108(30.33) | |
| PSM | yes | 106(29.78) | 51(14.33) |
| no | 140(39.33) | 59(16.57) | |
| SVI | Yes | 66(18.54) | 18(5.06) |
| no | 180(50.56) | 92(25.84) | |
| NI | yes | 143(40.17) | 69(19.38) |
| no | 83(23.31) | 41(11.52) | |
| ISUP grading | 1 | 30(8.43) | 48(13.48) |
| 2 | 19(5.34) | 13(3.65) | |
| 3 | 36(10.11) | 13(3.65) | |
| 4 | 42(11.80) | 32(8.99) | |
| 5 | 119(33.43) | 4(1.12) |